Ian Friedland MBBCh, MD

Dr. Ian Friedland joined Achaogen in 2014 as Chief Medical Officer. Prior to joining Achaogen, Dr. Friedland served as Vice President, Clinical Development at Cubist Pharmaceuticals, a publicly traded, global biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products addressing significant unmet medical needs in the acute care environment. At Cubist, he led the development of the anti-infectives, pain, and gastroenterology therapeutic areas while also managing the biostatistics, medical writing, clinical pharmacology and pharmacovigilence programs.
Specific anti-infective experience included leading the development of ceftolozane/tazobactam, surotomycin and late stage daptomycin studies. Before Cubist, Dr. Friedland was the Chief Medical Officer at Calixa Therapeutics, a San Diego-based private company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms, which was acquired by Cubist in December of 2009. Prior to Calixa, Dr. Friedland held senior managerial positions at Merck & Co where he served as Director, Clinical Research, Anti-Infectives and Johnson & Johnson as Senior Director, Clinical Research.
Dr. Friedland is a graduate of the University of the Witwatersrand, Johannesburg, South Africa, and the University of Texas Southwestern Medical School where he was a Fellow in pediatric infectious disease. He was a resident at Einstein Medical School and Montefiore Hospital, Bronx, NY and Baragwanath Hospital, Johannesburg, South Africa.